Belgian biotech Agomab Therapeutics NV will begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol "AGMB".
The company will offer 12.5 million American Depositary Shares ("ADSs"), representing 12.5 million of its common shares, at a public offering price of $16.00 per ADS. The offering is scheduled to close on February 9, 2026, and is expected to generate gross proceeds of $200 million.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.